Literature DB >> 24485800

Modafinil combined with cognitive training is associated with improved learning in healthy volunteers--a randomised controlled trial.

J Gilleen1, P G Michalopoulou2, A Reichenberg2, R Drake3, T Wykes2, S W Lewis3, S Kapur2.   

Abstract

Improving cognition in people with neuropsychiatric disorders remains a major clinical target. By themselves pharmacological and non-pharmacological approaches have shown only modest effects in improving cognition. In the present study we tested a recently-proposed methodology to combine CT with a 'cognitive-enhancing' drug to improve cognitive test scores and expanded on previous approaches by delivering combination drug and CT, over a long intervention of repeated sessions, and used multiple tasks to reveal the cognitive processes being enhanced. We also aimed to determine whether gains from this combination approach generalised to untrained tests. In this proof of principle randomised-controlled trial thirty-three healthy volunteers were randomised to receive either modafinil or placebo combined with daily cognitive training over two weeks. Volunteers were trained on tasks of new-language learning, working memory and verbal learning following 200 mg modafinil or placebo for ten days. Improvements in trained and untrained tasks were measured. Rate of new-language learning was significantly enhanced with modafinil, and effects were greatest over the first five sessions. Modafinil improved within-day learning rather than between-day retention. No enhancement of gains with modafinil was observed in working memory nor rate of verbal learning. Gains in all tasks were retained post drug-administration, but transfer effects to broad cognitive abilities were not seen. This study shows that combining CT with modafinil specifically elevates learning over early training sessions compared to CT with placebo and provides a proof of principle experimental paradigm for pharmacological enhancement of cognitive remediation.
Copyright © 2014 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Keywords:  Cognitive enhancement; Cognitive training; Learning; Modafinil

Mesh:

Substances:

Year:  2014        PMID: 24485800     DOI: 10.1016/j.euroneuro.2014.01.001

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  9 in total

Review 1.  Developing treatments for cognitive deficits in schizophrenia: the challenge of translation.

Authors:  J W Young; M A Geyer
Journal:  J Psychopharmacol       Date:  2014-12-16       Impact factor: 4.153

Review 2.  Benefits and Harms of 'Smart Drugs' (Nootropics) in Healthy Individuals.

Authors:  Fabrizio Schifano; Valeria Catalani; Safia Sharif; Flavia Napoletano; John Martin Corkery; Davide Arillotta; Suzanne Fergus; Alessandro Vento; Amira Guirguis
Journal:  Drugs       Date:  2022-04-02       Impact factor: 9.546

3.  Evaluation of the Efficacy of BI 425809 Pharmacotherapy in Patients with Schizophrenia Receiving Computerized Cognitive Training: Methodology for a Double-blind, Randomized, Parallel-group Trial.

Authors:  Philip D Harvey; Christopher R Bowie; Sean McDonald; Jana Podhorna
Journal:  Clin Drug Investig       Date:  2020-04       Impact factor: 2.859

4.  The off-prescription use of modafinil: An online survey of perceived risks and benefits.

Authors:  Rachel D Teodorini; Nicola Rycroft; James H Smith-Spark
Journal:  PLoS One       Date:  2020-02-05       Impact factor: 3.240

5.  An experimental medicine study of the phosphodiesterase-4 inhibitor, roflumilast, on working memory-related brain activity and episodic memory in schizophrenia patients.

Authors:  James Gilleen; Yakub Farah; Cate Davison; Sarah Kerins; Lorena Valdearenas; Tolga Uz; Gez Lahu; Max Tsai; Frank Ogrinc; Avi Reichenberg; Steve C Williams; Mitul A Mehta; Sukhi S Shergill
Journal:  Psychopharmacology (Berl)       Date:  2018-12-08       Impact factor: 4.415

6.  The effect of training intensity on implicit learning rates in schizophrenia.

Authors:  Natasza D Orlov; Jessica Sanderson; Syed Ali Muqtadir; Anastasia K Kalpakidou; Panayiota G Michalopoulou; Jie Lu; Sukhi S Shergill
Journal:  Sci Rep       Date:  2021-03-22       Impact factor: 4.379

Review 7.  Cognitive dysfunction in schizophrenia: An expert group paper on the current state of the art.

Authors:  Philip D Harvey; Marta Bosia; Roberto Cavallaro; Oliver D Howes; René S Kahn; Stefan Leucht; Daniel R Müller; Rafael Penadés; Antonio Vita
Journal:  Schizophr Res Cogn       Date:  2022-03-22

8.  How cognitive enhancement can change our duties.

Authors:  Filippo Santoni de Sio; Nadira Faulmüller; Nicole A Vincent
Journal:  Front Syst Neurosci       Date:  2014-07-17

Review 9.  Pharmacological Augmentation of Psychosocial and Remediation Training Efforts in Schizophrenia.

Authors:  Philip D Harvey; Michael Sand
Journal:  Front Psychiatry       Date:  2017-09-25       Impact factor: 4.157

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.